Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indaptus TherapeuticsINDP -9.79%30 3-Year EBITDA Growth Rate is 25.90% as of Mar. 2026, which is 463% above its 10-year median of 4.60. GuruFocus rates INDP with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,136 Biotechnology companies, Indaptus Therapeutics ranks better than 62.15% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Indaptus Therapeutics was 25.90% per year. The lowest was -43.10% per year. And the median was 4.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Indaptus Therapeutics 3-Year EBITDA Growth Rate Related Terms
INDP vs UPB, RCKT, DMAC: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Indaptus Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.90% mean?
Indaptus Therapeutics (INDP) has a 3-Year EBITDA Growth Rate of 25.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Indaptus Therapeutics and its competitors. This is 463% above median its historical median of 4.60. According to the industry distribution chart, Indaptus Therapeutics ranks #430 out of 1136 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Indaptus Therapeutics' 3-Year EBITDA Growth Rate too high?
Indaptus Therapeutics' current 3-Year EBITDA Growth Rate of 25.90% is 463% above median its 10-year median of 4.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Indaptus Therapeutics' value of 25.90% is 74.4% above this industry median. Based on the distribution chart, Indaptus Therapeutics ranks #430 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Indaptus Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' 3-Year EBITDA Growth Rate compare to UPB and RCKT?
According to the Biotechnology industry distribution chart, Indaptus Therapeutics ranks #430 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Indaptus Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Indaptus Therapeutics' value of 25.90% is 74.4% above this benchmark. While the company's 10-year median is 4.60 vs. the industry median of 14.85, Indaptus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indaptus Therapeutics's current 3-Year EBITDA Growth Rate of 25.90% is 74.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Indaptus Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indaptus Therapeutics's current 3-Year EBITDA Growth Rate is 25.90%, which is 463% above median its own 10-year median of 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current 3-Year EBITDA Growth Rate of 25.90%. The current 3-Year EBITDA Growth Rate is 25.90%, which is 463% above median its 10-year median of 4.60 and 74.4% above the Biotechnology industry median of 14.85. Indaptus Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current 3-Year EBITDA Growth Rate is 25.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
30GF Score
Get the complete analysis for INDP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDP has been successfully added to your 
